EQUILLIUM, INC. Proceeds from Sale of Available-for-sale Securities, Equity
EQUILLIUM, INC. (EQ) reported Proceeds from Sale of Available-for-sale Securities, Equity of $15.00 million for the 1-month period ending 2017-05-31, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity · last filed 2019-11-12
- 2017-05-31: Proceeds from Sale of Available-for-sale Securities, Equity 1 month $15.00M.
| Period end | Proceeds from Sale of Available-for-sale Securities, Equity 1 month |
|---|---|
| 2017-05-31 | $15.00M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |